Literature DB >> 15980395

In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.

Katsuko Fujikawa1, Megumi Chiba, Mayumi Tanaka, Kenichi Sato.   

Abstract

The in vitro activities of DX-619, des-fluoro(6) quinolone, against 1,208 clinical isolates were examined. DX-619 was particularly potent against staphylococci, including ciprofloxacin- and methicillin-resistant strains; the MIC at which 90% of the strains tested were inhibited was 0.5 microg/ml. In addition, DX-619 was also active against gram-negative bacteria.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15980395      PMCID： PMC1168666          DOI： 10.1128/AAC.49.7.3040-3045.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.

Authors:  Soju Chang; Dawn M Sievert; Jeffrey C Hageman; Matthew L Boulton; Fred C Tenover; Frances Pouch Downes; Sandip Shah; James T Rudrik; Guy R Pupp; William J Brown; Denise Cardo; Scott K Fridkin
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

2.  Infectious disease 2001: drug resistance, new drugs.

Authors:  Nafsika H Georgopapadakou
Journal:  Drug Resist Updat       Date:  2002-10       Impact factor: 18.500

3.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998.

Authors:  D F Sahm; M E Jones; M L Hickey; D R Diakun; S V Mani; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

Review 4.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.

Authors:  F J Schmitz; A C Fluit; S Brisse; J Verhoef; K Köhrer; D Milatovic
Journal:  FEMS Immunol Med Microbiol       Date:  1999-12

6.  [In vitro susceptibilites to levofloxacin and various antibacterial agents of 11,475 clinical isolates obtained from 52 centers in 2002].

Authors:  Keizo Yamaguchi; Akira Ohno; Fusako Kashitani; Morihiro Iwata; Makoto Kanda; Yoshiko Tsujio; Norihiko Shimoyama; Hidetoshi Okujima; Minoru Ito; Hideaki Kawaguchi; Hitoshi Chiba; Koji Akizawa; Yosei Katayama; Kumiko Sugimoto; Hiromi Tashiro; Mitsuomi Kaimori; Akira Suwabe; Ritsuko Obata; Tatsuro Sugiyama; Shunkoh Toyoshima; Jun Kato; Mitsuo Kaku; Keiji Kanemitsu; Hiroyuki Kunishima; Jun Okada; Yoko Tazawa; Jun Igari; Toyoko Oguri; Kiyoaki Watanabe; Yoshio Kobayashi; Hiroshi Uchida; Kyoichi Totsuka; Shinichiro Kon; Katsuji Nakamura; Keiko Matsuda; Izumi Hayashi; Joji Shiotani; Joji Shiotani; Harushige Kanno; Akira Itoh; Midori Sumitomo; Takashi Uchida; Atushi Kawabata; Chikashi Oiwa; Masamitsu Iwata; Toshinobu Horii; Shiomi Ishigo; Taira Yoshimura; Satoshi Ichiyama; Yasunao Wada; Satoshi Kimura; Shigefumi Maesaki; Kouichi Itoh; Yasunobu Noda; Takanori Yamashita; Ikuo Yamaguchi; Fumio Kageyama; Etsuko Shaku; Hisashi Baba; Kazuhisa Inuzuka; Hidetoshi Okabe; Kenichi Tatewaki; Kunihiko Moro; Masanori Aihara; Toshiharu Matsushima; Yoshihito Niki; Masao Kuw Abara; Siro Ikawa; Mobuaki Tanaka; Yasuharu Hinoda; Tetsuro Sugiura; Mikio Kamioka; Junko Ono; Tohru Takata; Hideichi Makino; Mitsuharu Murase; Hisashi Miyamoto; Hisamichi Aizawa; Junichi Honda; Masahide Takii; Zenzo Nagasawa; Yosuke Aoki; Naotaka Hamazaki; Toshiharu Tsutsui; Keiichi Nakagawa; Morihiro Iwata; Kazufumi Hiramatsu; Tetsunori Saikawa; Nobuhisa Yamane; Hiroya Kimoto; Tomio Kotani; Takeshi Kageoka; Toshiharu Hongo; Junichi Masuda; Hiroaki Miyanohara; Masayuki Tsujimura; Minoru Yasujima; Izumi Hayashi
Journal:  Jpn J Antibiot       Date:  2005-02

7.  Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).

Authors:  D Mathai; R N Jones; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  2001-07       Impact factor: 2.803

8.  High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999.

Authors:  Jan M Bell; John D Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid.

Authors:  Sibtain Rahim; Satish K Pillai; Howard S Gold; Lata Venkataraman; Kenneth Inglima; Robert A Press
Journal:  Clin Infect Dis       Date:  2003-05-20       Impact factor: 9.079

10.  Vancomycin-resistant enterococci in King Chulalongkorn Memorial Hospital: a 5-year study.

Authors:  Sumanee Nilgate; Pongpun Nunthapisud; Anan Chongthaleong
Journal:  J Med Assoc Thai       Date:  2003-06
View more
  14 in total

1.  Effects of statins on multispecies oral biofilm identify simvastatin as a drug candidate targeting Porphyromonas gingivalis.

Authors:  Marta Kamińska; Ardita Aliko; Annelie Hellvard; Ewa Bielecka; Veronika Binder; Agata Marczyk; Jan Potempa; Nicolas Delaleu; Tomasz Kantyka; Piotr Mydel
Journal:  J Periodontol       Date:  2018-12-26       Impact factor: 6.993

2.  In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.

Authors:  D Molitoris; M-L Väisänen; M Bolaños; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Intracellular penetration and activity of DX-619 in human polymorphonuclear leukocytes.

Authors:  Isabel García; Sofía Ballesta; Concepción Murillo; Evelio J Perea; Alvaro Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Molecular characteristics and in vitro susceptibility to antimicrobial agents, including the des-fluoro(6) quinolone DX-619, of Panton-Valentine leucocidin-positive methicillin-resistant Staphylococcus aureus isolates from the community and hospitals.

Authors:  Tatsuo Yamamoto; Soshi Dohmae; Kohei Saito; Taketo Otsuka; Tomomi Takano; Megumi Chiba; Katsuko Fujikawa; Mayumi Tanaka
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

5.  Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.

Authors:  Nenad Sarapa; Prachi Wickremasingha; Nanxiang Ge; Richard Weitzman; Merynda Fuellhart; Cindy Yen; Julia Lloyd-Parks
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

6.  In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.

Authors:  Paul A Wickman; Jennifer A Black; Ellen Smith Moland; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms.

Authors:  Paul A Wickman; Ellen Smith Moland; Jennifer A Black; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

8.  DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.

Authors:  Jacob Strahilevitz; Que Chi Truong-Bolduc; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

9.  Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.

Authors:  Klaudia Kosowska-Shick; Kathy Smith; Tatiana Bogdanovich; Lois M Ednie; Ronald N Jones; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

10.  Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects.

Authors:  Yuichiro Imamura; Nobuyuki Murayama; Noriko Okudaira; Atsushi Kurihara; Katsuhisa Inoue; Hiroaki Yuasa; Takashi Izumi; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2012-10-17       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.